Compare multi-agent consensus ratings, forecast paths, AI price targets, expected return, fundamentals, analyst disagreement, risks, and the investment thesis across short- and long-term horizons.

CRSP.NASDAQ

CRISPR Therapeutics

Healthcare | Biotechnology

Gene editing company developing transformative therapies using CRISPR/Cas9 technology for genetic diseases and cancer.

Flagship Insight

How a Hidden Pipeline Shift Could Redefine the Future of Genomic Medicine

High consensus across reports indicates that while near-term commercialization of ex-vivo therapies faces severe logistical bottlenecks, the long-term investment thesis hinges on the clinical validation of a highly scalable, wholly-owned in-vivo pipeline. A fortress balance sheet provides critical insulation against restrictive global macroeconomic rate headwinds.

Forecast TimelineUpdated On Jul 02 2026

CRISPR Therapeutics (CRSP) Stock Forecast and AI Rating

Recommendation

Small Buy

Open a small position; wait before adding more.

2027

1-Year

BUY

$64

+6.3%

+29% IF INCL. DIVS

2029

3-Year

N/A

$95

+98%

2031

5-Year

BUY

$139

+131%

+188% IF INCL. DIVS

LATEST DEEP FORECAST ANALYSIS BY iPULSE AI ENGINE | Jul 05, 2026

Visionary, Superintelligence, Insider, Strategist, Value Seeker, Vulture, Whistleblower, and more.

Elon Musk (Visionary), Superintelligence (Anthropologist), Machiavelli (Insider), Ray Dalio (Strategist), Warren Buffett (Value Purist), Michael Burry (Vulture), Sherlock Holmes (Whistleblower).

Research support only. We don't give financial advice.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Grok

Investment Thesis Takeaway

Expert LanguageExpert Quant Language

Explained Simply

Interactive forecast chart

Expert Language

Explained Simply

The overarching base-case narrative projects a structural transition from high-friction, low-throughput ex-vivo cellular therapies to highly scalable, high-margin in-vivo genomic platforms. While near-term performance is constrained by restrictive monetary policy, elevated discount rates, and slow commercial adoption of early-stage assets, the company's unassailable liquidity buffer provides absolute insulation against capital market closure. This financial fortress allows organic pipeline progression through the cycle trough, positioning the asset for a powerful long-term re-rating as clinical data matures.

Key insights

The transition to in-vivo lipid nanoparticle delivery represents a massive expansion in addressable market, shifting the business model from rare diseases to broad-population chronic indications.
A fortress balance sheet with substantial cash reserves eliminates near-term refinancing risks and prevents dilutive capital raises during restrictive credit cycles.
Near-term commercialization of ex-vivo therapies remains bottlenecked by complex manufacturing, patient conditioning logistics, and slow treatment center activation.
Geopolitical supply chain decoupling and regulatory frameworks like the BIOSECURE Act favor Western-domiciled intellectual property and domestic manufacturing assets.
Next-generation base and prime editing platforms present a durable competitive threat, demanding constant R&D reinvestment to avoid technological obsolescence.
High discount rates under the hawkish monetary regime will continue to compress the present value of long-duration cash flows, capping near-term multiple expansion.

Preparing your access...

AI Consensus

AI Opinions

Company Profile

CRISPR Therapeutics quarterly forecast scenarios

One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.

Quarterly Bear Case, Base Case, Bull Case, and S&P 500 benchmark forecasts for CRISPR Therapeutics.
Quarter	Forecast date	Bear Case (USD)	Base Case (USD)	Bull Case (USD)	S&P 500 benchmark (USD)
Quarter 1+3M	Oct 02, 2026	$55.27	$58.48	$62.48	$736.09
Quarter 2+6M	Jan 02, 2027	$51.96	$59.77	$66.23	$724.14
Quarter 3+9M	Apr 02, 2027	$49.36	$60.14	$69.49	$713.57
Quarter 4+1Y	Jul 02, 2027	$47.38	$62.09	$70.39	$723.38
Quarter 5+15M	Oct 02, 2027	$48.25	$63.88	$74.15	$716.61
Quarter 6+18M	Jan 02, 2028	$45.84	$67.46	$85.27	$738.34
Quarter 7+21M	Apr 02, 2028	$44.54	$70.03	$95.50	$746.91
Quarter 8+2Y	Jul 02, 2028	$42.76	$74.68	$103.14	$771.93
Quarter 9+27M	Oct 02, 2028	$44.89	$75.24	$97.99	$782.73
Quarter 10+30M	Jan 02, 2029	$46.24	$82.01	$115.63	$807.31
Quarter 11+33M	Apr 02, 2029	$45.32	$86.36	$138.75	$822.72
Quarter 12+3Y	Jul 02, 2029	$47.13	$92.13	$159.56	$846.10
Quarter 13+39M	Oct 02, 2029	$48.07	$95.46	$153.18	$852.53
Quarter 14+42M	Jan 02, 2030	$46.63	$102.47	$191.48	$882.91
Quarter 15+45M	Apr 02, 2030	$48.96	$104.90	$210.62	$900.46
Quarter 16+4Y	Jul 02, 2030	$50.43	$113.32	$235.90	$922.67
Quarter 17+51M	Oct 02, 2030	$52.45	$119.12	$247.69	$935.91
Quarter 18+54M	Jan 02, 2031	$51.40	$126.47	$267.51	$952.30
Quarter 19+57M	Apr 02, 2031	$54.48	$130.48	$283.56	$976.28
Quarter 20+5Y	Jul 02, 2031	$56.66	$139.06	$311.91	$1,002

Alpha Gap and Advisor Disagreement

Alpha Gap

The core information gap lies in a fundamental duration mismatch and a misunderstanding of the platform's structural evolution. While the crowd obsessively focuses on the slow, near-term commercial ramp of ex-vivo therapies, they systematically ignore the non-linear potential of the in-vivo pipeline. Ex-vivo treatments are highly complex, low-throughput medical procedures, whereas in-vivo delivery via lipid nanoparticles functions as a highly scalable, high-margin biological software update. Furthermore, the market misprices the company's massive cash reserves as a liability under a high-rate regime, failing to recognize that this fortress balance sheet provides absolute immunity to capital scarcity, allowing the firm to fully fund its transition to an in-vivo platform without dilutive financing. This creates an asymmetric margin of safety near the cash-adjusted floor.

Advisor Disagreement

The primary disagreement across reports centers on the commercial horizon and risk weighting of the ex-vivo launch versus the in-vivo pipeline. Some perspectives adopt a near-term, forensic focus, emphasizing the immediate cash burn and the loss-sharing nature of the joint venture. Conversely, other views prioritize a longer-term horizon, assuming that the slow ex-vivo rollout is merely a temporary logistical bottleneck and that the true terminal value resides in the highly scalable in-vivo platform. There is also minor disagreement regarding whether recent convertible debt issuance represents a defensive buffer or an offensive strategic weapon.

Financial Reviews by iPulse AI

Earnings and financials

The company is currently in a classic transition phase from a research-focused business to a commercial one, which makes its current financial numbers look highly unusual. Recent reports show a major drop in revenue and large operating losses because early milestone payments have faded while its first approved drug is just starting to roll out. There is strong agreement that near-term earnings will remain deeply negative due to high research spending and the complex costs of launching a new therapy. However, opinions differ on how quickly this will turn around. Some expect a slow, painful path to profitability because of high shared expenses with its commercial partner, while others believe that once the drug scales up, high-margin royalties will quickly shrink these losses. Ultimately, the company's massive cash reserves ensure it can survive this heavy spending phase without financial distress.

Profitability and margins

Currently, the company's profit margins are deeply negative and mathematically distorted because it is spending heavily on research while generating very little initial revenue. There is a clear clash in how analysts view the future margin outlook. Some warn that the high logistical costs of personalized cell therapies will keep profit margins thin for several years, especially under shared-profit agreements. Others argue that once the company transitions to direct-to-patient therapies, the profit margins will behave like software, where every new sale is almost pure profit because the core technology has already been developed. The critical signal to watch is whether the company can successfully launch a direct-to-patient therapy, which would bypass the expensive hospital logistics and unlock massive, long-term profitability.

Balance sheet and leverage

There is absolute consensus that the company's balance sheet is an unassailable financial fortress. With nearly two billion dollars in cash and short-term investments and virtually zero debt, the company is completely insulated from high interest rates and tight credit markets. This exceptional financial safety provides a comfortable four-to-six-year runway to fund expensive clinical trials without needing to borrow money or issue new shares that would dilute existing investors. While some reports view the recent issuance of convertible debt as a minor warning sign that organic cash flows are still years away, all agree that this massive cash pile is the company's greatest defense. It gives management the rare freedom to focus on long-term scientific breakthroughs without worrying about short-term market panic or bankruptcy risks.

Capex and investment intensity

The company's heavy spending is not going toward traditional physical assets like factories, but is instead heavily focused on research and development to build its future pipeline. There is high consensus that this massive investment is necessary to transition from complex, personalized treatments to simpler, direct-to-patient therapies. Some reports highlight that the company has also invested defensively in local manufacturing facilities in the United States, which creates a strong protective moat against foreign competitors and supply chain disruptions. While this aggressive spending temporarily drains cash and pressures near-term profits, it is viewed as an offensive move to secure market leadership. Analysts agree that investors must closely monitor clinical trial progress to ensure this heavy spending is successfully creating valuable, patent-protected treatments rather than simply burning through cash.